Phenobarbital sodium - نتائج البحث

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

extended phenytoin sodium- phenytoin sodium capsule

remedyrepack inc. - phenytoin sodium (unii: 4182431bjh) (phenytoin - unii:6158tkw0c5) - phenytoin sodium 100 mg - extended phenytoin sodium capsules, usp are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. phenytoin is contraindicated in patients with: - a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins [see warnings and precautions (5.5)] . a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins [see warnings and precautions (5.5)] . - a history of prior acute hepatotoxicity attributable to phenytoin [see warnings and precautions (5.6)]. a history of prior acute hepatotoxicity attributable to phenytoin [see warnings and precautions (5.6)]. - co-administration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors. co-administration with delavirdine because of the potential for loss of vir

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

sodium valproate sandoz sodium valproate 500mg enteric coated tablet blister pack

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: hyprolose; calcium silicate; amaranth aluminium lake; titanium dioxide; polyvinyl acetate phthalate; diethyl phthalate; stearic acid; purified talc; povidone; hypromellose; magnesium stearate; macrogol 6000; indigo carmine aluminium lake; citric acid monohydrate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

sodium valproate sandoz sodium valproate 200mg enteric coated tablet blister pack

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; polyvinyl acetate phthalate; indigo carmine aluminium lake; hyprolose; magnesium stearate; povidone; stearic acid; amaranth aluminium lake; diethyl phthalate; purified talc; macrogol 6000; calcium silicate; hypromellose; titanium dioxide - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

phenobarbital tablet

hikma pharmaceuticals usa inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 15 mg - phenobarbital tablets, usp are indicated for use as a sedative or anticonvulsant. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. in such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. a personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates. phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. it should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction. controlled substance: phenobarbital is a schedule iv drug. prolonged, uninterrupted use of barbiturates (particularly the short-acting drugs), even in therapeutic doses, may result in psychic and physical dependence. withdrawal symptoms due to physical dependence following chronic use of large doses of barbiturates may include delirium, convulsions, and death.